X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

NSF International Acquires Majority Interest in Amarex CRO

Content Team by Content Team
10th October 2019
in Market Moves
NSF International Acquires Majority Interest in Amarex CRO

NSF International has acquired a majority interest in Amarex Clinical Research, a clinical stage contract research organization (CRO) headquartered in Germantown, Maryland. The transaction supports NSF International’s mission of protecting and improving human health through expanded consulting services to the medical device and pharma/biotech industries. As part of NSF International’s global health science consulting business, the highly-respected CRO will be known as Amarex Clinical Research, an NSF International company.

Amarex Clinical Research will gain access to NSF International’s expert network and international scope. As part of NSF’s global network of locations, Amarex will continue to operate from its U.S. office near Washington, D.C. The company also operates an office in Taiwan and has a developing presence in Europe.

“NSF International plays an important role in the pharmaceutical and biotech industry as a champion of quality, scientific rigor and best practices aimed at protecting and improving human health. Together with Amarex, we are creating a single source for integrated, expert health science consulting services across the entire product lifecycle,” said NSF International President and CEO Kevan Lawlor. “Amarex brings clinical trial expertise to NSF International’s large base of training, quality and consulting clients, and Amarex’s CRO clients may now benefit from NSF International’s global reach and expertise in European Union Qualified Person and Medical Device Regulation training, chemistry manufacturing and controls support, and supplement testing inspection and certification.”

“Amarex is excited to join the NSF International family. Amarex will be able to leverage NSF International’s global infrastructure to expand our contract research capabilities and better serve clients with the design and execution of clinical trials and navigating the FDA, TFDA and EMA regulatory approval process,” said Amarex founder Dr. Kazem Kazempour, who will continue as president and CEO of Amarex, an NSF International company. “NSF International’s operational excellence will accelerate our expert team’s leap forward in the CRO market, and better help pharmaceutical, biotech and medical device/diagnostic companies develop products and services that will protect and improve human health while minimizing inefficiencies to save time and reduce unnecessary costs.”

Since 1998, Amarex Clinical Research has been helping biotech, medical device and pharmaceutical companies conduct scientifically sound clinical trials and navigate complex regulatory environments in a wide range of therapeutic indications, including oncology, central nervous system, wound healing, infectious disease, cardiovascular and urology.

As part of NSF International, Amarex will support companies with regulatory affairs, project/trial management, clinical operations, biostatistics, data management, pharmacovigilance, data monitoring committees, medical writing and consulting.

Previous Post

Amgen declares positive results for 2 Phase 3 BLINCYTO studies

Next Post

Adaptimmune, Cryoport Announce Agreement for Monitored Cell Therapies Transport

Related Posts

Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Featured

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Next Post
Adaptimmune, Cryoport Announce Agreement for Monitored Cell Therapies Transport

Adaptimmune, Cryoport Announce Agreement for Monitored Cell Therapies Transport

Latest News

Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In